Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cholesterol: precursor to many lipid disorders.

P H Jones

    The American Journal of Managed Care
    |August 24, 2001
    PubMed
    Summary
    This summary is machine-generated.

    Lowering low-density lipoprotein cholesterol (LDL-C) significantly reduces coronary heart disease (CHD) risk. Aggressive LDL-C reduction in at-risk patients, identified by risk scores, offers greater CHD event reduction and improved outcomes.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Precancerous niche remodelling dictates nascent tumour persistence.

    Nature·2026
    Same author

    Modelling red blood cell optical trapping by machine learning improved geometrical optics calculations.

    Biomedical optics express·2023
    Same author

    Influence of slow light effect on trapping force in optical tweezers.

    Optics letters·2022
    Same author

    Mutant clones in normal epithelium outcompete and eliminate emerging tumours.

    Nature·2021
    Same author

    New approaches to pharmacosurveillance for monitoring prescription frequency, diversity, and co-prescription in a large sentinel network of companion animal veterinary practices in the United Kingdom, 2014-2016.

    Preventive veterinary medicine·2018
    Same author

    Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials.

    Diabetic medicine : a journal of the British Diabetic Association·2018

    Area of Science:

    • Cardiovascular Medicine
    • Public Health
    • Clinical Lipidology

    Background:

    • Coronary heart disease (CHD) is the leading cause of death in the US, with elevated low-density lipoprotein cholesterol (LDL-C) as a major risk factor.
    • National Cholesterol Education Program guidelines (ATP II and ATP III) have evolved to identify more patients eligible for lipid-lowering therapy.
    • Despite guideline updates, many eligible patients are not receiving treatment, and fewer than half achieve their LDL-C goals.

    Purpose of the Study:

    • To emphasize the critical need for lowering LDL-C to reduce coronary heart disease (CHD) risk.
    • To highlight the benefits of aggressive LDL-C reduction in at-risk populations.
    • To underscore the importance of identifying at-risk patients and ensuring treatment adherence.

    Main Methods:

    Related Experiment Videos

    • Review of randomized clinical trials and large-scale prevention trials evaluating lipid-lowering therapies, primarily statins.
    • Analysis of guideline recommendations from the Adult Treatment Panel (ATP) II and ATP III for CHD risk assessment and management.
    • Examination of treatment goal achievement rates among patients on lipid-lowering therapy.

    Main Results:

    • Lowering LDL-C demonstrably reduces the risk of fatal and nonfatal coronary events.
    • More aggressive LDL-C reductions yield greater CHD risk reduction, particularly in high-risk individuals.
    • The benefits of lipid-lowering therapy are more pronounced in patients with higher baseline CHD risk.

    Conclusions:

    • Aggressive LDL-C reduction is crucial for mitigating coronary heart disease (CHD) risk.
    • Targeting at-risk patients identified through risk prediction scoring systems is essential for maximizing therapeutic benefits.
    • Effective CHD risk management requires appropriate treatment implementation and ensuring patient compliance with lipid-lowering therapy.